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Abstract
Prostate cancer is the most commonly diagnosed and second most lethal malignancy in men, due mainly to a lack of
effective treatment for the metastatic disease. A number of recent studies have shown that activation of the purine
nucleoside receptor, adenosine A3 receptor (A3AR), attenuates proliferation of melanoma, colon, and prostate cancer
cells. In the present study, we determined whether activation of the A3AR reduces the ability of prostate cancer cells to
migrate in vitro and metastasize in vivo. Using severe combined immunodeficient mice, we show that proliferation and
metastasis of AT6.1 rat prostate cancer cells were decreased by the administration of A3AR agonist N
6-(3-iodobenzyl)
adenosine-5′-N -methyluronamide. In vitro studies show that activation of A3AR decreased high basal nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase activity present in these cells, along with the expression of Rac1
and p47phox subunits of this enzyme. Inhibition of NADPH oxidase activity by the dominant-negative RacN17 or short
interfering (si)RNA against p47phox reduced both the generation of reactive oxygen species and the invasion of these
cells on Matrigel. In addition, we show that membrane association of p47phox and activation of NADPH oxidase is
dependent on the activity of the extracellular signal–regulated kinase (ERK)1/2 mitogen-activated protein kinase path-
way. We also provide evidence that A3AR inhibits ERK1/2 activity in prostate cancer cells through inhibition of adenylyl
cyclase and protein kinase A. We conclude that activation of the A3AR in prostate cancer cells reduces protein
kinase A–mediated stimulation of ERK1/2, leading to reduced NADPH oxidase activity and cancer cell invasiveness.
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Introduction
In the United States, the number of new cases and deaths due to pros-
tate cancer were estimated at 186,320 and 28,660, respectively, for the
year 2008 [1]. The major cause of deaths is due to the complications
resulting from cancer metastases to distant organs in the body. The
5-year survival rate for the localized disease is close to 90% to 100%,
but it is just approximately 32% for the metastatic prostate cancer [1],
reflecting the lack of effective treatment for the metastatic disease,
associated with androgen insensitivity.
Cancer cell metastasis requires the cell to acquire an early motile
phenotype followed by transformation to an adhesive phenotype to
facilitate interaction with the extracellular matrix proteins. This allows
for dispersion of the malignant cells through the blood stream or lymph
vessels to other parts of the body [2]. The Rho family of small GTP
binding proteins, namely, Rac1 and Cdc42, play crucial roles in can-
cer cell metastasis [3]. Aberrant activation of these proteins promotes
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invasion of various cancers [4–6] through regulation of actin cyto-
skeletal structures [7].
In addition to its role in cell motility, Rac1 is also an essential com-
ponent of the nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase system, a major source of superoxide generation in the cell.
NADPH oxidase was initially thought to be expressed mainly in phago-
cytes where it contributes to killing of ingestedmicroorganisms through
the generation of superoxide [8]. However, NADPH oxidase subunits
are also expressed in other tissues [9]. Full enzyme activity is conferred
by four oxidase subunits, namely, gp91phox, p22phox, p47phox, and
p67phox [10]. Other proteins associated with activation of the holo-
enzyme include p40phox, Rap1A, and Rac1, whose activation promotes
NADPH oxidase activity and generation of reactive oxygen species
(ROS) [10].
Whereas it is known that ROS increase oncogenic transformation
by damaging DNA and increasing mutation rates, recent evidence
demonstrates that ROS activate cell signaling pathways to promote
proliferation and metastasis [11]. ROS act as signaling molecules of
growth factor receptors to activate mitogen-activated protein (MAP)
kinases such as p38, extracellular signal–regulated kinase (ERK), and
c-Jun N-terminal kinase [12]. These signaling pathways culminate
in the regulation of cell cycle proteins, thereby influencing the pro-
liferation of cancer cells. In the context of growth factor signaling,
NADPH oxidase plays a key role in generating ROS [10].
Adenosine-based drugs represent a novel class of compounds that
show antitumor effects against a number of different cancers. Four
major classes of adenosine receptors (ARs), namely, the A1, the A2A,
A2B, and A3AR [13], have been identified. Adenosine and different AR
agonists have been shown to affect the tumorigenicity of different can-
cer types. A1AR agonists inhibit the proliferation of various cancer cell
lines including epidermoid cancer cells [14] and human leukemia cells
[15], whereas activation of the A2BAR increased tumor growth [16].
Recent studies have shown an antitumorigenic action of A3AR agonists
against melanoma [17], colon [18], and prostate cancers [19]. The
mechanism underlying this action involves inhibition of cyclic AMP
production, leading to reduced protein kinase A (PKA) and glycogen
synthase kinase-3β activity, destabilization of β-catenin and suppression
of cyclin D1 and c-myc, cell cycle arrest, and/or apoptosis [20,21].
A3AR agonists were also shown to increase migration of human colon
cancer cells [22]. However, this observation was obtained in in vitro
hypoxic culture conditions. Induction of the A3AR occurs in several
types of cancer [21,23], when compared with normal adjacent tissue,
suggesting that these receptors could serve as potential molecular mark-
ers of these cancers.
In this study, we show that the A3AR agonist, IB-MECA, inhibits
in vivo tumor growth and metastasis of prostate cancer in mice, in
addition to inhibition of in vitro cell proliferation and invasion of pros-
tate cancer cells. This antitumor action involves suppression of high
ROS generation through the NADPH oxidase system, which is main-
tained through high ERK1/2 activity in these cells. We show that A3AR
suppresses ERK1/2 and NADPH oxidase activity by inhibiting a cyclic
AMP/PKA pathway in these cells.
Materials and Methods
Materials
N 6-(3-Iodobenzyl)adenosine-5′-N -methyluronamide (IB-MECA),
3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2 phenyl-4-propyl-3-pyridine
carboxylate (MRS1523), 4-(2-aminoethyl)benzenesulfonyl fluoride
hydrochloride (AEBSF), dibenziodolium chloride (DPI), 2-(2-amino-
3-methoxyphenyl)-4H -1-benzopyran-4-one (PD098059), 9-(tetra-
hydro-2-furanyl)-adenine (SQ22536), N -[2-(p-bromocinnamylamino)
ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-89), and bisindo-
lylmaleimide I hydrochloride (BIM) were obtained from Sigma Chemi-
cal, Co (St Louis, MO). Antibodies against adenosine A3 receptor
(A3AR), phospho-ERK1/2, ERK1/2, p47
phox Rac1, and Na+-K+
ATPase were purchased from Santa Cruz Biotechnology, Inc (Santa
Cruz, CA). Antibodies against β-actin and against Bax and p53 were
bought from Sigma Chemical, Co, and Cell Signaling Technology
(Danvers, MA), respectively. Cell culture media RPMI 1640 and
penicillin/streptomycin were obtained from Invitrogen (Carlsbad,
CA), whereas fetal bovine serum was from Atlanta Biologicals, Inc
(Lawrenceville, GA). All other reagents and supplies were of highest
available grade and were purchased from standard sources.
Cell Cultures
The rat prostatic carcinoma cell line AT6.1, and human prostate
cancer cell lines ALVA and PC3-MM were cultured in RPMI 1640
media supplemented with 10% fetal bovine serum, 50 U/ml peni-
cillin, and 25 μg/ml streptomycin. Cells were grown at 37°C in
the presence of 5% CO2 and 95% ambient air. The medium was
changed every second day, and the cells were passaged twice a week.
All the experiments were performed using confluent monolayers.
Immunocytochemistry
AT6.1, PC3-MM, or ALVA cells were cultured on glass coverslips.
Drug treatments were performed for 24 hours, and cells were fixed
with 4% paraformaldehyde. Cells were processed and imaged for
A3AR and Rac1 as described previously [24].
2′,7′-Dichlorodihydrofluorescein Diacetate Assay
After 12 hours of serum deprivation AT6.1, PC3-MM, or ALVA
cells were loaded with 5 μg/ml of 2′,7′-dichlorodihydrofluorescein
diacetate (H2DCFDA; EMD Biosciences, San Diego, CA) in 2 ml of
1× PBS. After incubation at 37°C for 20 minutes, cells were washed
with 1× PBS. First, baseline images were recorded by a confocal micro-
scope (Olympus America, Inc, Melville, NY) at 488 nm, and then the
image was captured after the addition of 1 μM IB-MECA. For other
treatment groups, cells were pretreated with either vehicle or A3AR
inhibitor MRS 1523 (1 μM) or NADPH oxidase inhibitors DPI
(10 μM) or AEBSF (100 μM) for 30 minutes before adding the dye.
Quantitation of the fluorescence intensity was performed by using
FluoView software (Olympus America, Inc, Melville, NY).
Preparation of Plasma Membrane and Cytosolic Extracts
Cytosolic and membrane extracts from whole cell lysates were iso-
lated as described previously [24]. To verify the purity of the membrane
isolates, we probed for the membrane-specific protein Na+-K+ ATPase.
High Na+-K+ ATPase levels were obtained in the membrane fraction by
Western blot analysis compared with the cytosol (data not shown).
Western Blot Analysis
Total cell lysates were used to quantitate activation/inhibition of
ERK1/2 and expression of Rac1, whereas membrane preparations
were made to study the expression of A3AR. Assays were performed
essentially as described previously [24]. Blots were visualized by
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exposure to Kodak XAR film (Fisher Scientific, Pittsburgh, PA) or by
using a charge-coupled device camera (Hitachi Genetic Systems,
MiraiBio, Inc, Alameda, CA). Quantitation of the bands was per-
formed with Un-Scan-It software (Silk Scientific, Inc, Orem, UT).
Transient Transfection of AT6.1 Cells
AT6.1 cells (2.0 × 105/ml) were seeded on coverslips in six-well cul-
ture plates and grown to 70% confluence. A mixture of 1 μg of plas-
mid DNA from vectors expressing constitutively active Rac (RacQL)
or dominant-negative Rac (RacN17) was used, and transfections with
ExGen500 were performed as described previously [25].
In Vitro Invasion Chamber Assay
The ability of prostate cancer cells to migrate through Matrigel-
coated membranes was measured using BD Biocoat Matrigel invasion
chambers (BD Biosciences, San Jose, CA). AT6.1, PC3-MM, and
ALVA cells (200,000 cells) were suspended in the culture media with-
out serum and were plated on the top compartment of the invasion
chamber followed by respective treatments. At the end of 24 hours,
the cell inserts were removed, and cells were carefully wiped from
the top surface of the membrane with a cotton swab. The invasive cells
adhering to the bottom surface of the membrane were stained with
toluidine blue and quantified under a light microscope using a 20×
objective. Total number of invaded cells was counted in eight ran-
domly chosen fields per treatment per insert. To study the effects of
the short interfering RNA (siRNA)–p47 and Rac1 plasmids, AT6.1
cells were transfected with siRNA-p47 and siRNA-negative for 72 hours
or with empty vector or constitutively active (RacQL) or dominant-
negative (RacN17) plasmids for 12 hours before seeding them on the
top compartment.
Cell Proliferation Assay (MTS Assay)
In vitro prostate cancer cell proliferation was performed by using
CellTiter 96 AQueous One Solution Cell Proliferation Assay Kit
(Promega, Madison, WI), according to the manufacturer’s instructions.
In brief, 1 to 3 × 103 cells per well were seeded into a 96-well plate.
After respective treatments, cells were allowed to grow for 72 hours.
After 72 hours, 20 μl of CellTiter 96 AQueous One Solution reagent
was added to each well in 100 μl of total volume. Cells were incu-
bated for 3 to 4 hours, and absorbance was recorded at 490 nm using
a plate reader.
Apoptosis Detection
For detecting apoptosis in AT6.1 cells, apoptotic cells were visual-
ized using fluorimetric TdT-FragEL DNA fragmentation detection
kit performed according to the manufacturer’s instructions (EMD
Biosciences). Briefly, the cells were treated with vehicle, IB-MECA,
or positive control for 24 hours. After the treatments, the cells were
washed with cold 1× PBS and fixed with 4% paraformaldehyde. Fixed
cells were permeabilized with 20 μg/ml of proteinase K for 5 minutes,
washed with 1× TBS, and placed in 1× TdT equilibrating buffer for
20 minutes. Cells were then incubated in labeling reaction buffer
containing Fluorescein-FragEL TdT labeling reaction mix and TdT
enzyme for 60 minutes at 37°C in a humidified chamber. After one
wash with 1× TBS and 10 minutes of incubation in blocking buffer,
cells were mounted on glass slide and visualized by confocal micro-
scope. Apoptotic cells were identified as those emitting bright green
fluorescence, whereas control/nonapoptotic cells were either nonfluores-
cent or faintly green fluorescent.
Cyclic AMP Assay
Cyclic AMP levels were measured with a chemiluminescence-
based cyclic AMP HTS immunoassay kit from Millipore (Billerica,
MA) according to the manufacturer’s instructions.
Modified Wound-Healing Assay
Equal number of cells were plated in each well of six-well culture
plates. After the cells reached 70% to 80% confluence, one half of
the well was denuded by scraping off the cells with a cell scraper. The
images were recorded before and just after the denudation (time,
0 hours). Cells were then treated with different reagents and incubated
for another 24 hours, and differential interference contrast (DIC)
images of the cells were captured by confocal microscopy. For quanti-
tation, cells were counted in five random fields in the marked area and
normalized to vehicle-treated controls.
In Vivo Studies
To determine the spontaneous metastatic ability of the AT6.1
prostate tumor cells, 0.5 × 106 cells in 0.2 ml of 1× PBS were in-
jected intravenously through the tail vein of 5-week-old severe com-
bined immunodeficient (SCID) mice with an average weight of 20 g
(Harlan Sprague-Dawley, Indianapolis, IN). Mice were divided into
two treatment groups, namely, control and IB-MECA groups, and
treatments were started at the same time of tumor cell injections.
Control mice were treated with 200 μl of vehicle (dH2O), whereas
IB-MECA–treated mice received 10 μg/kg of IB-MECA in a final
volume of 200 μl. Vehicle or drug was administered on alternate days
by intraperitoneal (i.p.) injections. Mice were killed 3 weeks after the
injection of the cells, and metastatic lesions on the lungs were
counted macroscopically. For effects on tumor growth, drug admin-
istration was performed as described above, but the tumor cells were
inoculated subcutaneously in the dorsal flank of the mice, and treat-
ments were started after 9 days when the tumor size reached 100 mm3.
The tumor sizes were measured twice a week with a caliper, and the
tumor volume was calculated using the formula, tumor volume =
(W 2) × (L / 2), where W represents the width and L represents the
tumor length. The tumor size was measured until day 33 after tumor
inoculation, after which the mice were killed, and tumors were re-
moved and flash-frozen for Western blot studies. In the same group
of mice, a number of metastatic lesions were counted on the lungs
to measure the effect of IB-MECA on the metastatic ability of
AT6.1 cells after subcutaneous inoculation of tumor cells.
siRNA Transfections
siRNA transfections were done using RNAi human/mouse starter
kit from Qiagen (Valencia, CA) according to the manufacturer’s pro-
tocol. Briefly, 3 to 4 × 105 AT6.1 cells were plated. Next day, dif-
ferent concentrations (0-50 nM) of p47phox siRNA were diluted in
100-μl serum-free medium and were incubated at room temperature
for 5 to 10 minutes with 3 μl of HiPerFect transfection reagent
(Qiagen) to allow the formation of transfection complexes, which
were added to the cell cultures by gently swirling the plates. Cells
were incubated for another 72 hours and later used for quantitating
p47phox by Western blot analysis. For all other subsequent experi-
ments, the same protocol was used with 50 nM p47phox siRNA.
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RNA Preparation, Reverse Transcription, and Polymerase
Chain Reaction
Isolation of total RNA from cells was performed by using Tri reagent
(Sigma Chemical, Co), as directed by the manufacturer. The respec-
tive products were normalized to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH).
Real-time Reverse Transcription–Polymerase Chain Reaction
Total RNA was isolated and converted to complementary DNA
using iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA), and quantitative reverse transcription–polymerase chain reaction
(RT-PCR) was performed as described previously [25]. The PCR
products were resolved on 2% agarose gel and viewed with SyBRGreen
dye. Gel intensity analysis was performed by using Un-Scan-It software.
PCR Primers
The set of primer sequences were from SigmaGenosys (St Louis,MO).
A3AR:
5′-CATCTGGGTGGTCAAGCTGAA-3′ (sense);
5′-ACCGTTCTATATCTGACTGTC-3′ (antisense).
Rac1:
5′-ATCAGTTACACGACCAATGC-3′ (sense);
5′-GGGAAAAGCAAATTAAGAAC-3′ (antisense).
p47phox:
5′-CATGTTCCTGGTTAAGTGGCA-3′ (sense);
5′-AGGTGTGGGCAGCGGGAGATC-3′ (antisense).
GAPDH:
5′-ATGGTGAAGGTCGGTGTGAAC-3′ (sense);
5′-TGTAGTTGAGGTCAATGAAGG-3′ (antisense).
Protein Determination
The levels of protein in samples were determined by Bio-Rad
protein detection reagent using bovine serum albumin to prepare stan-
dard curves.
Statistical Analyses
Statistical analyses were performed by using analysis of variance
followed by Tukey’s honestly significant difference post hoc test to com-
pensate for multiple pairwise comparisons or by paired Student’s t test.
Results
A3AR Agonist IB-MECA Inhibits Proliferation and Invasion
of Prostate Cancer Cells
To study the effects of A3AR on tumor cell growth and invasion, we
performed in vitro studies using the androgen-independent metastatic
human prostate carcinoma cells (PC3-MM), the androgen-dependent
human prostate carcinoma cells (ALVA), and the androgen-independent
highly metastatic rat prostate carcinoma cells (AT6.1). These cell lines
expressed A3AR, as demonstrated in Figure 1A by RT-PCR (top left),
Western blot analysis (top right), and immunocytochemistry (bottom).
To determine whether A3AR activation inhibits proliferation of prostate
cancer cells, MTS assays were performed in the presence of IB-MECA
(1 μM), an agonist of the A3AR, with or without the selective an-
tagonist MRS1523 (1 μM). Figure 1B demonstrates that exposure
to IB-MECA for 72 hours led to significant reductions in proliferation
of these cells to 59 ± 2%, 50 ± 6%, and 64 ± 3% of vehicle-treated
controls for PC3-MM, ALVA, and AT6.1 cells, respectively. This
antiproliferative response was reduced by MRS1523; the respective pro-
liferative indices in these lines were 98 ± 7%, 111 ± 14%, and 96 ± 6%of
vehicle-treated controls (Figure 1B). We did not obtain any significant
inhibition of proliferation of these cells after exposure to IB-MECA for
24 hours. For AT6.1 cells, the cell numbers obtained after 24 hours of
exposure to IB-MECA, MRS1523, and IB-MECA + MRS1523 were
89 ± 8%, 96 ± 9%, and 88 ± 7% of control.
To assess the effects of A3AR activation on prostate cancer cell in-
vasion and migration in vitro, we used Matrigel invasion chamber
and wound-healing assays, respectively. Treatment with IB-MECA
(1 μM) for 24 hours decreased the number of invaded cells, as seen
by toluidine blue staining of the cells on Matrigel membrane, to
47 ± 3%, 49 ± 1%, and 38 ± 8% of vehicle-treated controls in
PC3-MM, ALVA, and AT6.1 cell lines, respectively. This inhibition
by IB-MECAwas significantly reduced by MRS1523 (Figure 1C), im-
plicating the A3AR in this process. In addition, IB-MECA reduced the
migration of AT6.1 cells, as demonstrated by reduced cell migration
in wound-healing assays. IB-MECA decreased migration to 52 ± 2%
of vehicle-treated controls, which was blocked by coadministration of
IB-MECA with MRS1523 (Figure 1D). These data indicate that acti-
vation of the A3AR suppresses both the proliferation and invasion/
migration of prostate cancer cells in vitro. However, it seemed that these
two processes are independent of each other because significant inhibi-
tion of invasion and migration was observed at 24 hours, a time point
when no effect on cell proliferation was evident.
Cells exposed to IB-MECA for 24 hours did not show any increase
in apoptotic cell death, as determined by TdT-FragEL DNA fragmen-
tation assay in cells (Figure W1A). In addition, IB-MECA did not in-
crease the levels of proapoptotic proteins Bax and p53 (Figure W1, B
and C ). These results further support the lack of inhibition of prolifera-
tion of prostate cancer lines obtained at 24 hours inMTS assays. Never-
theless, continued exposure to IB-MECA for 48 and 72 hours increased
the levels of Bax and p53 (data not shown). These data suggest that
the reduction in cell number obtained at 72 hours in the presence of
IB-MECA could result, in part, from increased apoptosis.
IB-MECA Inhibits In Vivo Prostate Tumor Growth
and Metastasis
To determine the relevance of our in vitro findings, we examined
tumor growth and metastasis of AT6.1 prostate cancer cells in a SCID
mouse model. AT6.1 cells were injected subcutaneously into the dor-
sal flank of SCID mice and when the tumor size was approximately
100 mm3 (by approximately day 9), these mice were administered
either vehicle or IB-MECA (10 μg/kg body weight, i.p.) on alternate
days. Figure 2A shows a progressive increase in tumor volumes over
time in mice administered vehicle but significantly reduced tumor sizes
in mice administered IB-MECA. Tumor volumes measured on day 14
were 573 ± 57 mm3 in vehicle-treated control mice and 276 ± 52 mm3
after IB-MECA treatment (n = 6; P < .01). On days 23 and 33, tumor
volumes were 2794 ± 142 and 6153 ± 721 mm3, respectively, for the
controls but were reduced to 1276 ± 127 and 2261 ± 646 mm3 after
IB-MECA treatments (n = 6; P < .01). Examination of the lungs from
these animals indicates that subcutaneous injection of AT6.1 cells re-
duced lung metastasis. The number of lesions observed in vehicle-
treated mice was 37 ± 8 and was significantly reduced to 12 ± 1 in mice
treated with IB-MECA. These data indicate that IB-MECA could re-
duce both prostate tumor sizes and metastasis in vivo.
To exclude the possibility that the reduced tumor metastasis pro-
duced by IB-MECA after subcutaneous injections of tumor cells was
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independent of its action on proliferation, we induced experimental
tumor metastasis by injecting AT6.1 cells intravenously through the
tail vein. IB-MECA (10 μg/kg body weight, i.p.) was administered
at the time of cell administration and on alternate days for 3 weeks.
Mice were then killed, lungs were isolated, and metastatic lesions
were counted macroscopically. As shown in Figure 2B, this method
of administration of the prostate cancer cells dramatically increased
the number of metastatic lesions in the lung. Administration of
IB-MECA significantly reduced the number of metastatic lesions
in the lungs from 208 ± 18 in vehicle-treated mice to 89 ± 29 by
IB-MECA–treated mice (Figure 2C ). These data support the finding
that IB-MECA inhibits prostate cancer metastasis in vivo by blocking
extravasation of cells to the lung.
A3AR Agonist Reduces High ROS Generation in Prostate
Cancer Cells by Inhibiting NADPH Oxidase
ROS plays an important role in oncogenesis by regulating genes
involved in proliferation and metastasis of cells [11], which could
account for the metastatic phenotype of tumor cells. To test whether
IB-MECA alters ROS generation in these cells, we assessed its pro-
duction using H2DCFDA. AT6.1 cells showed high basal ROS levels,
and incubation of cells with IB-MECA (1 μM) produced a rapid,
time-dependent reduction in ROS generation, as demonstrated by
the reduction in the green fluorescence (Figure 3A). Similar results were
obtained with IB-MECA in ALVA and PC3-MM cells (Figure W2).
The inhibition by IB-MECA was blocked in cells pretreated with
1 μM MRS1523 (Figure 3A), implicating the A3AR in this process.
ROS generation was 41 ± 5% of vehicle-treated controls in the presence
of IB-MECA and 82 ± 8% in cells pretreated with MRS1523 before
IB-MECA administration (Figure 3B). In addition, inhibition of
NADPH oxidase with 10 μMDPI and 100 μM AEBSF effectively re-
duced ROS generation in these cells to 37 ± 9% and 45 ± 8% of con-
trol, respectively (Figure 3, C and D). However, inhibition of xanthine
oxidase or nitric oxide synthase with allopurinol or N -nitro-L-arginine
methyl ester (L-NAME), respectively, did not alter the level of ROS ob-
served in these cells (data not shown). These results implicate NADPH
oxidase in the generation of high ROS in these cells, which was inhib-
ited by IB-MECA and NADPH oxidase inhibitors.
To confirm a role of NADPH oxidase as a source of ROS genera-
tion in AT6.1 cells, we targeted p47phox and Rac1, subunits of this
Figure 1. A3AR agonist IB-MECA inhibits proliferation and invasion of different prostate cancer cell lines. (A) Expression of A3AR in pros-
tate cancer cell lines, PC3-MM, ALVA, and AT6.1, was determined by RT-PCR (top left), Western blot analysis (top right), and immuno-
cytochemistry (bottom). The pictures shown are the representation of three different experiments with similar results. (B) PC3-MM, ALVA,
and AT6.1 cells were plated in a 96-well plate and treated with vehicle or IB-MECA (1 μM) or MRS1523 (1 μM) or MRS1523 with IB-MECA
for 72 hours. Cell proliferation was assessed by MTS assays. Values represented are mean ± SEM of four different experiments, each of
which shows the average data obtained from 16-well per treatment group. Asterisk (*) indicates statistically significant difference (P< 0.01)
from control, whereas (**) indicates statistically significant difference (P < 0.01) from IB-MECA–treated cells. (C) Cells were plated on the
top chamber of the Matrigel invasion chamber. Treatments were performed for 24 hours and numbers of invaded cells were counted on
the membranes stained with toluidine blue. Numbers depicted in histogram are mean ± SEM of three separate experiments, each per-
formed with duplicate chambers per treatment group. Asterisks (*) and (**) indicate statistically significant difference (P< .05) from control
and IB-MECA treatment groups, respectively. (D) AT6.1 cells migration in cultures was assessed by modified wound-healing assays in
which at 70% to 80% confluence, half of cell cultures were denuded by scraping the cells with a cell scraper at time 0 hours. The cells
were imaged (middle panel) and treated with vehicle or IB-MECA (1 μM) or MRS1523 (1 μM) or MRS1523 + IB-MECA for 24 hours. After
24 hours, DIC images were obtained of the marked denuded area. Five random fields were chosen for images (right panel), and numbers of
cells were counted per field and were represented in the bar graph as the mean ± SEM of three different experiments. Asterisks (*) and
(**) indicate statistically significant difference (P < .05) from vehicle-treated control and IB-MECA treated cells, respectively.
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enzyme, for inhibition. Knockdown of p47phox was produced by
transfecting cells with siRNA (50 nM) for 72 hours. This concentration
of p47phox siRNA was based on dose-response studies of siRNA on
p47phox protein levels (Figure W3A), which showed significant suppres-
sion of p47phox by Western blot analysis at a concentration of 50 nM.
Control cultures were administered a similar concentration of a scram-
bled siRNA (siRNA-neg) sequence and tested concurrently.We observed
that knockdown of p47phox reduced the high ROS generation (Figure 4,
A and B) with no further inhibition observed with IB-MECA adminis-
tration (data not shown). p47phox siRNA reduced ROS generation to
33 ± 6% of control cells. To determine a role of Rac1 in the generation
of ROS, cells were transiently transfected with an empty vector, a plas-
mid construct expressing the constitutively active (RacQL) or dominant-
negative mutant (RacN17) forms of Rac1. Transfection efficiency using
ExGen500 in these cells averaged approximately 80 ± 10%, similar to
that observed previously [25]. To show the levels of Rac1 expression in
the cells transfected with the mutant plasmids, we performed RT-PCR
and immunocytochemistry on the cells 24 hours after transfections. In-
creased Rac1 mRNAwas detected in cells transfected with either RacQL
or RacN17 plasmids, compared with cells transfected with the empty
vector (Figure W3B). The levels of Rac1 mRNA detected were 160 ±
8% and 160 ± 11% of empty vector, for RacQL and RacN17 transfec-
tants, respectively. In addition, increased Rac1 immunolabeling was de-
tected in cells RacQL and RacN17 transfectants, compared with empty
vector (FigureW3C). Higher immunolabeling for Rac1 was observed in
the RacN17-transfected group (approximately 85% of cells per high-
power field) and RacQL (approximately 92% of cells per high-power
field) compared with empty vector (approximately 50% of cells per
high-power field).
AT6.1 cells expressing the empty vector or RacQL demonstrated high
ROS generation, whereas the cells transfected with RacN17 plasmid
showed significantly lower levels of ROS generation (Figure 4, D and
E). IB-MECA failed to inhibit the ROS generation in the presence of
constitutively active RacQL (data not shown), suggesting that its action
ismediated through inhibition of an upstream regulator of Rac1 function.
We next examined the role of ROS generation through NADPH
oxidase in AT6.1 cell invasion. Knockdown of p47phox or inhibition
of Rac1 (as previously mentioned) significantly reduced the invasion
of AT6.1 cells compared with cells treated with a scrambled siRNA
sequence (siRNA-Neg) or untransfected cells (vehicle; Figure 4, C
and F ). The numbers of invaded cells were 53 ± 3% and 35 ± 3%
of control, in the presence of p47phox siRNA and RacN17, respectively.
Interestingly, the expression of RacQL did not alter the level of invasion
above that observed for the control cells, likely indicating that Rac1 is
already maximally active in these cells. From these data, we conclude
that NADPH oxidase plays a crucial role in regulation of ROS genera-
tion, which regulate the metastatic phenotype of AT6.1 cells.
IB-MECA Inhibits Activation and Expression of NADPH
Oxidase Subunits
The inactive form of the p47phox subunit of NADPH oxidase re-
sides in cytoplasm, which on activation by phosphorylation, trans-
locates to the plasma membrane where it interacts with other subunits
to form the holoenzyme needed to generate superoxide [9]. Thus, the
Figure 2. IB-MECA suppresses prostate tumor growth and metastasis in mice. (A) Highly metastatic dunning rat prostate cancer (AT6.1)
cells were injected subcutaneously in the dorsal flank of SCID mice. After 9 days, one group of mice was administered vehicle (control),
whereas the other group was treated with 10 μg/kg IB-MECA (six mice per group). Tumor sizes were measured twice a week until day 33 of
tumor inoculation. Asterisk (*) indicates statistically significant difference (P < .01) from control mice. (B) For experimental metastasis
assays, mice were injected intravenously (through tail vein) with AT6.1 cells (four mice per group). Mice were treated with vehicle or
IB-MECA on alternate days, starting from the day of cancer cell injection. After 3 weeks, mice were killed, and total numbers of metastatic
lesions were counted in lungs. Representative pictures show lungs from two animals from each treatment group. (C) Summary of the
effect of IB-MECA on lung metastases in SCID mice.
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degree of p47phox plasma membrane localization could serve as an indi-
cator of NADPH oxidase activity in AT6.1 cells. Figure 5A shows high
levels of p47phox in the plasma membrane compared with the cytosolic
fraction in the absence of any drug treatments. However, IB-MECA
decreased p47phox in the membrane fraction but increased cyto-
solic p47phox (Figure 5A). This effect of IB-MECA was inhibited by
MRS1523, supporting a role of the A3AR in decreasing p47
phox
translocation (Figure 5B). In addition, 24 hours of administration of
IB-MECA reduced the steady-state expression of p47phox and Rac1
mRNA, with the respective mRNA levels being 0.5 ± 0.1- and 0.4 ±
0.1-fold of the control cells. Pretreatment with MRS1523 reversed
the inhibition by IB-MECA, as demonstrated by p47phox and Rac1
mRNA levels of 1.1 ± 0.2- and 1.0 ± 0.1-fold of control in cells pre-
treated with MRS1523 followed by IB-MECA (Figure 5C). IB-MECA
also inhibited expression of p47phox and Rac1 protein, as demonstrated
in Figure 5, D and E , respectively. In the presence of 24 hours of
IB-MECA treatment, the p47phox levels were 51 ± 9% of vehicle-
treated controls, whereas they were 100 ± 14% in the cells pretreated
with MRS1523 before IB-MECA treatment (Figure 5D). However,
IB-MECA did not alter the expression of the p22phox and p67phox sub-
units of NADPH oxidase in AT6.1 cells but reduced the expression
of the gp91phox homolog Nox1 (data not shown). These data indicate
that the A3AR inhibits both p47
phox membrane localization and the
expression of p47phox and Rac1.
Additional studies were performed to determine whether similar
changes in p47phox and Rac1 could be induced in vivo by IB-MECA
administration in SCID mice bearing AT6.1 subcutaneous tumors.
AT6.1 cells were injected subcutaneously into the dorsal flank of
SCID mice and IB-MECA treatment (10 μg/kg body weight, i.p.)
was initiated when the tumor size was approximately 100 mm3 (by
day 9) and continued on alternate days until day 33. Subcutaneous
tumors were excised and used for Western blot analysis. We observed
a significant suppression of p47phox expression by IB-MECA in the
primary tumor to 52 ± 13% of control (Figure 6, A and B). Similarly,
Rac1 expression was reduced to 36 ± 6% of the expression level of
vehicle-treated mice (Figure 6, C and D).
A3AR Inhibition of p47
phox Involves Inhibition of ERK1/2
MAP Kinase Activity
To determine the mechanism underlying IB-MECA inhibition of
p47phox membrane localization, we focused on ERK1/2 MAP kinase
signaling because this kinase mediates phosphorylation and activa-
tion of p47phox subunit in the immune system [26,27]. Inhibition of
MAP kinase kinase, the immediate upstream activator of ERK1/2 by
PD098059 (10 μM) reduced ROS generation to 42 ± 12% of control
after a 15-minute treatment period (Figure 7A). PD098059 also altered
the localization of p47phox in these cells. The levels of p47phox in mem-
branes were 50 ± 14% and 57 ± 12% of controls after 5 and 15minutes
of PD098059 treatment, respectively (Figure 7B). There was a cor-
responding increase in cytosolic levels of p47phox. After 5 and 15 min-
utes of treatment with PD098059, the cytosolic levels of p47phox were
167 ± 30% and 223 ± 39% of vehicle-treated cells (Figure 7C ).
Figure 3. A3AR mediated reduction of ROS generation in prostate cancer cells. (A and B) AT6.1 cells were pretreated for 30 minutes with
either vehicle or 1 μMMRS1523 and then incubated with H2DCFDA for 20 minutes. IB-MECA (1 μM) was added to the cells after recording
baseline images, and subsequent images were recorded 15 minutes after addition of the drug with a confocal microscopy. Images shown
are representative of four different experiments showing similar results. Quantitation of fluorescent images by FluoView software is pre-
sented in panel B. Similar experiments were performed in cells pretreated with 10 μM DPI or 100 μM AEBSF (C). Quantitation of fluores-
cent images from panel C is shown in panel D. Histograms represent the mean ± SEM of four different experiments. Asterisks (*) and (**)
indicate statistically significant difference (P < .05) from vehicle and IB-MECA treatments, respectively.
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Because the preceding data suggest a potential role of ERK1/2 in reg-
ulating the activation of p47phox in AT6.1 cells, we next determined
whether IB-MECA inhibits ERK1/2 activation in AT6.1 cells. As
shown in Figure 7D, we observed high levels of p-ERK1/2 in AT6.1
cells, which were reduced to 31 ± 6% and 21 ± 5% of control levels
by exposure to IB-MECA for 5 and 15 minutes, respectively, compara-
ble to the effect of PD098059. This inhibitory effect of IB-MECA was
dose-dependent (Figure W6) and was reduced by A3AR antagonist
MRS1523 (Figure 7E), implicating A3AR activation in this process.
ERK1/2 activity was also regulated by high ROS because treat-
ment of cells with DPI (10 μM) and AEBSF (100 μM) both reduced
the p-ERK1/2 activation (Figure W4). These results suggest that
whereas ERK1/2 is important for NADPH oxidase activity, the activ-
ity of ERK1/2 is also dependent on NADPH oxidase, implying the
existence of a positive feedback loop between these two enzymes in
these cells.
A3AR Inhibition of ERK1/2 MAP Kinase Activity Is Mediated
through Cyclic AMP/Protein Kinase A Pathway
The A3AR is negatively coupled to adenylyl cyclase through the
Gi protein, leading to a decrease in cyclic AMP levels and inhibition
of PKA [28]. To determine whether A3AR activation in AT6.1 cells
regulates adenylyl cyclase activity, we determined cyclic AMP levels
in cells treated with IB-MECA. Basal levels of cyclic AMP in these
cells were 12.8 ± 0.6 pmol per well. Treatment of AT6.1 cells with
IB-MECA significantly reduced the cyclic AMP generation to 6.3 ±
2.2 pmol per well (n = 3; P < .05). Pretreatment of cells with MRS1523
reversed the inhibition by IB-MECA to 12.6 ± 4.0 pmol per well (Fig-
ure W5), implicating the A3AR in the inhibition of adenylyl cyclase.
To determine in more detail whether inhibition of the cyclic AMP
pathway is important in mediating the antineoplastic actions of A3AR
activation, we examined the roles of adenylyl cyclase and PKA, we used
the inhibitors SQ22536 [29] and H-89 [30], respectively. As shown in
Figure 8A, 20 μM H-89 and 100 μM SQ22536 both attenuated the
high ERK1/2 activity in AT6.1 cells. At 5 minutes, p-ERK1/2 was
69 ± 5% and 74 ± 9% of control, whereas at 15 minutes it was 49 ±
6% and 53 ± 10% of control in the presence of H-89 (Figure 8A, left
panel ) and SQ22536 (Figure 8A, middle panel ), respectively. Because
protein kinase C (PKC) is a known regulator of p47phox activation,
we determined the role of PKC in these cells by using the selective in-
hibitor, BIM. BIM (1 μM) did not significantly change the p-ERK1/2
levels at the two time points examined (Figure 8A, right panel ).
Figure 4. NADPH oxidase mediates ROS generation and invasion of AT6.1 cells. (A and B) AT6.1 cells were transfected with a siRNA
against p47phox (siRNA-p47phox) or scrambled-siRNA (siRNA-neg) for 72 hours (A), and ROS generation was determined by incubating
the cells with H2DCFDA. siRNA-p47
phox suppressed ROS generation. Histograms shown in panel B represent the mean ± SEM of three
separate experiments. Asterisk indicates statistically significant difference (P< .01) from vehicle-treated controls. (C and D) AT6.1 cells were
transfected with an empty plasmid vector or an expression vector encoding the constitutively active (RacQL) or dominant-negative (RacN17)
Rac1 plasmids for 24 hours. ROS generation in these cells was imaged (D) and quantitated in (E) and shows suppression of ROS in RacN17
transfectants but comparable levels of ROS, as observed in empty vector, in RacQL transfectants. Invasion chamber assays were performed
in cells transfectedwith vehicle, siRNA-Neg, or siRNA-p47phox (C) or with Rac1mutants (F). Histograms indicate the extent ofMatrigel invasion
from three different experiments. Inhibition of cell invasion was observed in cells treated with siRNA-p47phox and RacN17. Asterisk indicates
statistically significant difference from control (P < .01).
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Pretreatment of AT6.1 cells with either H-89 or SQ22536 signifi-
cantly reduced ROS generation, whereas PKC inhibitor BIM did not
have any effect (Figure 8B). In addition, both H-89 and SQ22536
reduced the membrane localization of p47phox (Figure 8C ), whereas
BIM showed no significant effect (Figure 8D). These data implicate
the cyclic AMP/PKA pathway in the activation of ERK1/2 and the
NADPH oxidase system. Whereas PD098059, H-89, and SQ22536
significantly suppressed invasion of AT6.1 cells to 46 ± 3%, 35 ± 5%,
and 48 ± 6% of controls, respectively, BIM did not affect AT6.1 cells
invasion (Figure 8E).
Discussion
This study demonstrates that activation of the A3AR reduces prolifera-
tion and metastasis of prostate cancer cells both in vitro and in vivo. We
have identified two major targets of the A3AR crucial for regulating
both proliferation and invasion. These are the ERK-MAP kinase path-
way and NADPH oxidase, an important regulator of ROS generation
in prostate cancer cells. Furthermore, ERK1/2 activity and NADPH
oxidase activity in these cells seemed to be dependent on the activity
of adenylyl cyclase and PKA because inhibition of both the enzymes
reduced ERK1/2 activation as well as ROS generation and cell invasion.
The incidence and prevalence of prostate cancer increase with in-
creasing age, and one of the important risk factors linked to this in-
creased propensity is the generation of high levels of ROS in the
prostate cancer cells. ROS is normally produced as part of the aerobic
cellular respiration, and low to moderate levels of ROS play a critical
role in the intracellular signaling pathways [31]. However, the levels
of ROS within the cells become high, whereas the levels of the anti-
oxidant enzymes are reduced with aging [32]. In the present study,
we observed high levels of ROS in different prostate cancer cell lines,
including the human PC3-MM and ALVA and rat AT6.1 cell lines.
The high levels of ROS are believed to directly damage cellular DNA
and proteins, which might further aggravate malignant transformation.
A link between high ROS and prostate cancer is indirectly supported
by the studies showing that antioxidants such as lycopene, vitamin E,
selenium, and soy can reduce the risk of prostate cancers [33].
One of the major sources of ROS generation in the cells is the
NADPHoxidase enzyme system. Previous studies have shown increased
Figure 5. Inhibition of p47phox activity and Rac1 expression by A3AR activation. (A) Western blot analysis for p47
phox was performed in
membrane and cytosolic fractions from AT6.1 cells after 1 μM IB-MECA treatment for indicated time points. Vehicle-treated cells served as
controls. Blots were stripped and probed for β-actin to normalize for protein loading. The figure shows reduced membrane localization and
increased cytosolic levels of p47phox at 5 and 15 minutes after IB-MECA administration. Histograms represent the mean ± SEM of four
different Western blot experiments quantified by Un-Scan-It software. Asterisk (*) indicates statistically significant difference (P< .05) from
control. (B) AT6.1 cells were pretreated with MRS1523 for 30 minutes, followed by IB-MECA treatment for 5 minutes, and membrane and
cytosolic isolates were obtained for p47phox Western blot studies. MRS1523 reduced the ability of IB-MECA to reduce membrane locali-
zation (or increase cytosolic localization) of p47phox. The blot presented is a representative from five different experiments with identical
results. (C) AT6.1 cells were treated with vehicle, IB-MECA (1 μM), MRS1523 (1 μM), or MRS1523 + IB-MECA for 24 hours, and p47phox
and Rac1 transcripts were measured by real-time RT-PCR. Histograms indicate the mean ± SEM of the fold change in transcripts levels.
(D) Levels of p47phox determined by Western blot analysis. Cells were pretreated with vehicle or MRS1523 for 30 minutes followed by
IB-MECA for 24 hours. IB-MECA reduced p47phox levels, which was inhibited by MRS1523. Histograms indicate the mean ± SEM of at least
five different experiments. Asterisks (*) and (**) represent statistically significant difference from vehicle- and IB-MECA–treated groups, re-
spectively (P < .05). (E) Immunocytochemistry for Rac1 was performed on the cells grown on glass coverslips and treated with indicated
reagents for 24 hours. Fluorescent and DIC images are a representation from three independent experiments performed in duplicates.
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Figure 6. A3AR agonist decreases p47
phox and Rac1 levels in vivo. SCID mice were administered AT6.1 cells by subcutaneous injections.
When the tumor size was approximately 100 mm3 (∼day 9), these mice were administered vehicle or IB-MECA (10 μg/kg), and treat-
ments were continued on alternate day up to day 33. Subcutaneous tumors were then excised and used for Western blot analysis for
p47phox and Rac1. (A and B) Western blots and densitometric analyses of p47phox levels from four mice. (C and D) Western blots and
densitometric analyses of Rac1 levels from four mice. Data are presented as the mean ± SEM of four different experiments. Asterisk (*)
indicates statistically significant difference (P < .05) from vehicle-treated SCID mice.
Figure 7. ERK1/2 MAP kinase regulates NADPH oxidase activity. (A) AT6.1 cells were treated with either vehicle or PD098059 (10 μM) for
15 minutes. Cells were then incubated with H2DCFDA for 20 minutes, and ROS generation was recorded by confocal microscopy. The
histograms show the levels of ROS generation and represent the mean ± SEM of three different experiments. Asterisk (*) indicates statis-
tically significant difference from control (P < .01). (B and C) p47phox Western blot analysis was performed on isolated membrane (B) and
cytosolic (C) fractions of vehicle- or PD098059-treated cells. Representative blot shows reduced activation of p47phox, indicated by reduced
membrane level of p47phox by PD098059. Histograms represent the mean ± SEM of five different experiments. Asterisk (*) indicates sta-
tistically significant difference (P< .05) from vehicle-treated control cells. (D) IB-MECA reduced ERK1/2 activation in AT6.1 cells. The West-
ern blot image is a representative of six different experiments with similar results. Data presented in the histogram are the mean ± SEM.
Asterisk (*) indicates statistically significant difference from vehicle-treated controls (P < .01). (E) A3AR antagonist MRS1523 reduces in-
hibition of ERK1/2 phosphorylation by IB-MECA. Blot is representative of four separate experiments with identical results.
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ROS in the presence of prostate-specific antigen and testosterone in
both androgen-dependent (LNCaP) and -independent cell lines
(PC3 and DU145) [34]. Brar et al. [35] reported the involvement of
NADPH oxidase subunits, gp91phox and NOX5, in regulating the
growth of the androgen-independent DU145 prostate cancer cells.
Increased ROS generation and expression ofNOX1were also observed
in human prostate cancer specimens [36] and in ovarian cancer cells
where siRNA against NADPH oxidase subunits NOX4 and p47phox
reduced the high basal ROS generation [37]. Similarly, we also observed
high NADPH oxidase activity in various prostate cancer cell lines, in-
cluding both androgen-dependent and -independent lines, examined
in this study. The ability of chemical inhibitors such as DPI and AEBSF,
as well as of siRNA against p47phox and dominant-negative Rac1, to
inhibit ROS generation implicates NADPH oxidase as a major con-
tributor of ROS generation in these prostate cancer cells. The anti-
tumor action of IB-MECA seems to be linked to the inhibition of
NADPH oxidase in these cells. ROS can mediate mitogenic signal-
ing and regulate the actions of transcription factors, such as activator
protein-1 and nuclear factor κB and protein kinases, such as protein
kinase C and ERK1/2 MAP kinases [38]. Constitutive activation of
ERK1/2 has been observed in leukemia [39], breast cancer [40], and
ovarian cancer [41], where they might promote tumor metastasis in ad-
dition to cell proliferation. In melanoma cells, ERK1/2 increases the
cell invasion by activating matrix metalloproteinases (MMPs) such as
MMP-1, -2, and -9 [42]. Increased ERK1/2 activation has also been im-
plicated in the increased migration of PC3 prostate cancer cells in the
presence of lysophosphatidic acid [43]. These studies support the in-
volvement of ERK1/2 inmediating both cell proliferation andmetastasis.
In the present study, we show that the A3AR inhibits ERK1/2 ac-
tivity in AT6.1 cells presumably by inhibiting the activity of adenylyl
cyclase through the Gi protein(s), leading to reduced cyclic AMP levels
and activation of PKA. It seems that this adenylyl cyclase–PKA signal-
ing pathway is crucial for maintaining the high basal ERK1/2 activity
in these cells because inhibition of these enzymes reduced ERK1/2
Figure 8. Inhibition of the cyclic AMP/PKA pathway abrogates ERK1/2 activity. (A) AT6.1 cells were treated with H-89 (PKA inhibitor; 20 μM),
SQ22536 (adenylyl cyclase inhibitor; 100 μM) or BIM (PKC inhibitor; 1 μM) for 5 or 15 minutes. Western blot analysis was performed for
p-ERK1/2 and normalized to total ERK1/2. Histograms indicate the mean ± SEM of at least five separate experiments. Asterisk (*) indicates
statistically significant difference from control cells (P< .01). (B) AT6.1 cells were treated with H-89, SQ22536, and BIM for 15 minutes, and
ROS generation was determined bymeasuring the fluorescence of H2DCFDA dye. H-89 and SQ22536 decreased ROS generation, whereas
BIM was without effect. (C and D) AT6.1 cells were treated with vehicle, H-89, or SQ22536 (C) or BIM (D) for 5 and 15 minutes. Western
blot analysis was performed for p47phox on the membrane fraction. Blot shown is a representative of three separate experiments that show
similar results. (E) AT6.1 cells were plated on the top chamber of theMatrigel invasion chamber and treatedwith vehicle, PD098059 (10 μM),
H-89 (20 μM), SQ22536 (100 μM), or BIM (1 μM) for 24 hours. The number of invaded cells was determined as described in Materials and
Methods and normalized as percent of vehicle-treated controls. The histogram represents the mean ± SEM of three different experiments.
Asterisk (*) indicates statistically significant difference from vehicle-treated control cells (P < .05).
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activity. Activation of ERK1/2 activity by PKA is likely mediated at
the level of the B-Raf protein, which seems to serve as a substrate for
PKA [44]. Similar to our findings, inhibition of ERK1/2 phosphoryla-
tion by A3AR agonist has been demonstrated in melanoma [45] and
thyroid cancer cells [46]. In melanoma cells, the inhibition of ERK1/2
phosphorylation was dependent on A3AR and phosphatidylinositol
3-kinase/Akt activation [45]. Activation of phosphatidylinositol
3-kinase/Akt pathway resulted in the phosphorylation of Raf at an in-
hibitory site leading to decreased ERK1/2 activation [45]. In contrast,
A3AR agonists promoted ERK1/2 activity in colon cancer cell lines [47],
and A3AR transfected Chinese hamster ovary (CHO) cells [48]. The
reason for these differing responses in different cells is not clear but could
relate to the levels of basal ERK1/2 activity demonstrated in these cells.
For example, like prostate cancer, melanoma and thyroid cancer cells
might express high ERK1/2 activity, whereas colon cancer cell lines
and A3AR-transfected CHO cells might express low ERK1/2 activity.
In our study, we found that the inhibitory effects of A3AR agonist,
IB-MECA, were suppressed by the A3AR-specific antagonist MRS1523,
supporting our hypothesis that IB-MECA–induced effects were in fact
receptor-dependent. However, several studies have shown an A3AR-
independent effect of A3AR agonist in inducing apoptosis of leukemia
cells [49], breast cancer cells [50], HT-29 colon cancer cells [51], and
thyroid cancer cells [46]. In general, these responses were obtained at
high micromolar concentrations of the agonists, suggesting they might
involve activation of different ARs or other cellular targets.
Several pieces of evidence obtained from this study suggest that the
activity of NADPH oxidase is dependent on ERK1/2. For example,
we show that inhibition of ERK1/2 by PD098059 reduces plasma
membrane localization of p47phox in AT6.1 cells, a requirement for
the activation of this enzyme. This was correlated with increased cyto-
solic levels of p47phox. Such a pathway of ERK1/2 and p47phox interac-
tion could aid in the maintenance of the high ROS generation observed
in these cells. Activation of p47phox by ERK1/2 is well studied in human
neutrophils [26,27]. The primary sequence on substrates targeted by
ERK1/2 is Pro-Xaan-Ser/Thr-Pro, where Xaa is a neutral of basic amino
acid and n = 1 or 2 [52]. Human p47phox possess various serine residues
located in the C-terminus, which are phosphorylated during its activa-
tion [53]. Of these, Ser-345 and Ser-348 are located in target sequences
recognized by ERK1/2 (–Pro–X–Ser–Pro–), where X represents a neu-
tral or basic amino acid [53]. Rat p47phox also contains the ERK1/2 tar-
get sequence with serine residues at positions −346 and 349 [54], but
the mouse p47phox C-terminus is devoid of an ERK1/2 target sequence
[55]. Thus, unlike the mouse p47phox, the human and rat p47phox sub-
units are potential targets of ERK1/2–mediated phosphorylation, as
suggested by our findings.
In addition to the activation of NADPH oxidase system, ERK1/2
might also induce Rac1 activity or expression, as seen in colon cancer
cells and prostate cancer cells [56,57]. The high expression of Rac1
demonstrated in our study was also observed in a recent study by
Engers et al. [58], which showed high Rac1 expression in high-grade
prostatic intraepithelium neoplasia and prostatic carcinoma, compared
with benign secretory epithelium in human prostate tissue specimens.
Thus, Rac1 and p47phox not only are regulators of ROS generation but
also are regulated by ROS-dependent activation of the ERK1/2 path-
way. In breast cancer cells and squamous cell carcinoma, Rac1 activity
is stimulated by PKA, which promotes migration of these cancer cells
[59]. In the current study, we demonstrated that activation of the A3AR
(which inhibits adenylyl cyclase activity and expected to decrease PKA)
inhibited p47phox expression and prostate cancer cell invasiveness.
On the basis of the above discussion, it seems reasonable to speculate
that the mechanism underlying inhibition of prostate cancer cell pro-
liferation and metastasis through the A3AR involves suppression of
an adenylyl cyclase–PKA signaling pathway, which directly regulates
ERK1/2 MAP kinase and NADPH oxidase.
Whereas our study highlights the importance of controlling ROS
generation in the treatment of prostate cancers, we are not able to dis-
cern any differences in A3AR-mediated inhibition of cell proliferation
and motility in androgen-dependent (such as ALVA) and androgen-
independent prostate cancer lines (such as AT6.1 and PC3-MM). All
of these cell lines showed relatively similar responses to IB-MECA. This
suggests that IB-MECA could be useful in androgen-independent pros-
tate cancer, in which treatment options (such as androgen withdrawal
therapy) might be more limited. Furthermore, our studies did not
highlight any difference in the pathways linked to proliferation versus
metastasis. It seems that the ERK1/2 pathway might subserve both
functions. ERK1/2 can promote tumor cell proliferation by control-
ling the activity of different cell cycle regulators, such as increasing
the transcription of cyclin D1, activation of cyclin-dependent kinases
or inhibition of cyclin-dependent kinase inhibitor p27Kip1 [60]. In ad-
dition, ERK1/2 can also increase the tumor cell migration and invasion
by increasing the expression of Rac1 and MMP-1, -2, and-9 [42,57].
Inhibition of ERK1/2 activity by IB-MECA could therefore suppress
both prostate cancer cell proliferation and metastasis.
In summary, our data show that IB-MECA suppresses prostate cancer
growth and metastasis in vivo. This action is believed to be medi-
ated through suppression of the high NADPH oxidase activity in these
cells by inhibiting the upstream adenylyl cyclase/PKA pathway. PKA
positively regulates ERK1/2 activity, which serves as a direct activator
of p47phox subunit of NADPH oxidase. In addition, activation of the
A3AR reduced expression of the p47
phox and Rac1 subunits of this
enzyme and thereby removes the positive feedback regulation of ROS
generation in these cells. On the basis of our and other similar studies on
prostate cancers, we propose that A3AR agonists could be useful clini-
cally in controlling the growth and metastasis of androgen-dependent
and -independent prostate cancers.
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Figure W1. IB-MECA does not induce apoptosis of AT6.1 cells. (A) AT6.1 cells were cultured on glass coverslips and treated with vehicle,
IB-MECA, or actinomycin D (positive control) for 24 hours. Apoptotic cell death was assessed by TUNEL assays and detected as those
emitting bright green fluorescence. No significant apoptotic cells were detected in vehicle or IB-MECA–treated cultures. (B and C) Western
blot analysis experiments were performed on whole-cell lysates and probed for proapoptotic proteins Bax (B) and p53 (C). No difference
in Bax or p53 was observed with IB-MECA. The data presented in panels A, B, and C were replicated at least three different times and
showed similar results.
Figure W2. IB-MECA inhibits high ROS generation in PC3-MM
and ALVA prostate cancer cells. PC3-MM (A) and ALVA (B) cells
were cultured on glass coverslips, treated with vehicle or IB-MECA
(1 μM) for 15 minutes, then incubated with H2DCFDA for 20 min-
utes. ROS generation was reduced by IB-MECA in both cell lines.
The data presented in panels A and B were replicated at least three
different times and showed similar results.
Figure W3. Inhibition of p47phox (by siRNA) and Rac1 subunits (by RacN17) of NADPH oxidase in AT6.1 cells. (A) AT6.1 cells were trans-
fected with indicated doses of scrambled siRNA (0) or p47phox siRNA for 72 hours, and Western blot experiments were performed for
p47phox on whole cell lysates. (B) AT6.1 cells were transfected with empty vector, Rac1 dominant-negative plasmid (RacN17), or Rac1 con-
stitutively active plasmid (RacQL), and Rac1 expression was determined by RT-PCR. Increased Rac1 expression was observed in both
the RacN17 and RacQL transfectants compared with an empty vector. (C) Immunocytochemistry for Rac1 in Rac transfectants were per-
formed and visualized by confocal microscopy. Immunolabeling was increased in RacN17 and RacQL transfectants compared with cells
transfected with empty vector. The data presented in panels A, B, and C were repeated at least three times and show similar results.
Figure W4. ROS-dependent activation of ERK1/2. AT6.1 cells were
treated with vehicle, PD098059, DPI, or AEBSF for 24 hours, solubi-
lized, and used for detection of p-ERK1/2 by Western blot analysis.
Membranes were stripped and reprobed for ERK1/2 to normalize
for protein loading. The blot is a representative of four different ex-
periments with identical results. The histogram represents the nor-
malized p-ERK1/2 data, which are presented as the mean ± SEM of
four different experiments. Asterisk (*) indicates statistically signifi-
cant difference (P < .01) from vehicle-treated control cells.
Figure W5. A3AR activation reduces cyclic AMP (cAMP) levels in
AT6.1 cells. AT6.1 cells were pretreated with vehicle or MRS1523
(1 μM) for 30 minutes, followed by 5 minutes of IB-MECA (1 μM)
treatment. The cyclic AMP levels per culture well were then deter-
mined using a chemiluminescence-based cyclic AMP immunoassay
kit. Histogram represents mean ± SEM of three separate experi-
ments performed in quadruplates. Asterisk (*) indicates statistically
significant difference from vehicle-treated controls (P < .05).
Figure W6. Dose-dependent suppression of ERK1/2 activation by
IB-MECA. AT6.1 cells were treated with different doses of IB-MECA
(0-1000 nM) for 15 minutes, and Western blot analysis was per-
formed onwhole cell lysates for p-ERK1/2. Normalization of the blots
was donewith ERK1/2. The blot represents the identical results from
three separate experiments.
